- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.36 Referral Testing Agreement
- 23.1 Consent of Pricewaterhousecoopers LLP
- 23.2 Consent of Ernst & Young LLP
- 31.1 Certification of Chief Executive Officer Pursuant to Rule 13A-14(A)
- 31.2 Certification of Chief Financial Officer Pursuant to Rule 13A-14(A)
- 32.1 Certification of CEO & CFO Pursuant to Rule 13A-14(B)
EXHIBIT 23.1
CONSENT OF PRICEWATERHOUSECOOPERS LLP,
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements (Forms S-8 No. 333-43114, No. 333-89082 and No. 333-121437) pertaining to the 2000 Equity Incentive Plan, the 2000 Employee Stock Purchase Plan and 2004 Equity Incentive Plan of Monogram Biosciences, Inc. (formerly ViroLogic, Inc.) and in the Registration Statements (Forms S-3 No. 333-65716, No. 333-70562, No. 333-86892, No. 333-102273, No. 333-102995, No. 333-103980, No. 333-121438 and No. 333-121475) and related Prospectuses of Monogram Biosciences, Inc. (formerly ViroLogic, Inc.) of our report dated March 15, 2006 relating to the financial statements, financial statement schedule, management’s assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
March 15, 2006